Eksempler på brug af Rasagiline på Engelsk og deres oversættelser til Dansk
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
AZILECT 1 mg tablets rasagiline.
The metabolism of rasagiline proceeds through two main pathways.
Metaboliseringen af rasagilin sker via to hovedmetaboliseringsveje.What are the side effects of Azilect(Rasagiline Mesylate)?
Hvad er bivirkninger af Azilect(rasagilin mesylat)?Rasagiline pharmacokinetics are linear with dose over the range of 0.5-2 mg.
Rasagilins farmakokinetik er lineær i doser over 0, 5- 2 mg.How should I use Azilect(Rasagiline Mesylate)?
Hvordan skal jeg bruge Azilect(rasagilin mesylat)?Rasagiline produced statistically significant benefit compared to placebo.
Rasagilin viste statistisk signifikante fordele sammenlignet med placebo.Each tablet contains 1 mg rasagiline as mesilate.
Hver tablet indeholder 1 mg rasagilin som mesilat.AZILECT is a medicine containing the active ingredient rasagiline.
AZILECT er et lægemiddel, der indeholder det aktive stof rasagilin.It is not known whether rasagiline is excreted in human milk.
Det vides ikke, om rasagilin udskilles i modermælken.Azilect(Rasagiline Mesylate) is used to treat the symptoms of Parkinson's disease.
Azilect(Rasagilin Mesylat) bruges til behandling af Parkinsons sygdom.What are the side effects of Azilect(Rasagiline Mesylate)?
Hvad er bivirkningerne af Azilect(Rasagilin Mesylat)?Rasagiline is contraindicated in patients with severe hepatic insufficiency.
Rasagilin er kontraindiceret hos patienter med alvorligt nedsat leverfunktion.The active substance in AZILECT, rasagiline, is a monoamine oxidase-B inhibitor.
Det aktive stof i AZILECT, rasagilin, er en monoaminoxidase- B(MAO)- hæmmer.Rasagiline use in patients with moderate hepatic impairment should be avoided.
Brug af rasagilin til patienter med moderat nedsat leverfunktion bør undgås.If you are allergic(hypersensitive) to rasagiline or any of the other ingredients of AZILECT.
Hvis De er overfølsom(allergisk) over for det aktive stof rasagilin eller et af de øvrige.Rasagiline undergoes almost complete biotransformation in the liver prior to excretion.
Rasagilin gennemgår næsten fuldstændig metabolisering i leveren før udskillelse.Thus, potent CYP1A2 inhibitors may alter rasagiline plasma levels and should be administered with caution.
Potente hæmmere af CYP1A2 kan således ændre rasagilins plasmakoncentration og bør anvendes med forsigtighed.At least five weeks should elapse between discontinuation of fluoxetine and initiation of treatment with rasagiline.
Der bør gå mindst fem uger fra seponering af fluoxetin til iværksættelse af behandling med rasagilin.Experimental data indicated that rasagiline inhibits prolactin secretion and, thus, may inhibit lactation.
Data fra undersøgelser indikerede, at rasagilin hæmmer prolaktinsekretionen og derfor kan hæmme mælkedannelsen.In parentheses is the adverse reaction incidence(% of patients) in rasagiline vs. placebo, respectively.
I parentes er incidensen af bivirkninger(i procent af patienterne) angivet for henholdsvis rasagilin og placebo.Co-administration of rasagiline and ciprofloxacin(an inhibitor of CYP1A2) increased the AUC of rasagiline by 83.
Samtidig indgift af rasagilin og ciprofloxacin(en hæmmer af CYP1A2) øgede AUC af rasagilin med 83.Caution should be used when initiating treatment with rasagiline in patients with mild hepatic insufficiency.
Der bør udvises forsigtighed ved iværksættelse af behandling med rasagilin hos patienter med let nedsat leverfunktion.In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with rasagiline.
Efter markedsføring er disse symptomer også set hos patienter i behandling med rasagilin for Parkinsons syge.In the rasagiline clinical program overall 1361 patients were treated with rasagiline for 3076.4 patient years.
I kliniske undersøgelser med rasagilin blev i alt 1361 patienter behandlet med rasagilin i 3076, 4 patientår.At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with fluoxetine or fluvoxamine.
Der bør gå mindst 14 dage fra seponering af rasagilin til iværksættelse af behandling med fluoxetin eller fluvoxamin.Rasagiline did not present genotoxic potential in vivo and in several in vitro systems using bacteria or hepatocytes.
Rasagilin fremviste ikke genotoksisk potentiale in vivo og i adskillige in vitro systemer med bakterier eller hepatocyter.At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with MAO inhibitors or pethidine.
Der bør gå mindst 14 dage fra seponering af rasagilin til iværksættelse af behandling med MAO hæmmere eller pethidin.During the clinical development programme the occurrence of cases of melanoma prompted the consideration of a possible association with rasagiline.
Under det kliniske udviklingsprogram gav forekomsten There was also a statistically significant improvement over placebo with the rasagiline 0.5 mg group, yet the magnitude of improvement was lower.
Der sås også en statistisk signifikant forbedring These results indicate that rasagiline' s therapeutic concentrations are unlikely to cause any clinically significant interference with substrates of these enzymes.
Disse resultater tyder på, at terapeutiske koncentrationer af rasagilin sandsynligvis ikke giver anledning til klinisk relevant påvirkning 
